Literature DB >> 8952869

Induction of apoptosis by ubenimex (Bestatin) in human non-small-cell lung cancer cell lines.

K Ezawa1, K Minato, K Dobashi.   

Abstract

We studied the direct anti-tumor effects of ubenimex on five human lung cancer cell lines; ABC-1, RERF-LC-OK, RERF-LC-MS (adenocarcinoma) and SQ-5, EBC-1 (squamous cell carcinoma). Ubenimex dose-dependently inhibited the growth of these cancer cell lines except RERF-LC-MS. The results indicated that lung squamous cell carcinoma cell lines were more sensitive to ubenimex than lung adenocarcinoma cell lines. Coincidentally, histological observation by Hematoxylin eosine (HE) staining revealed that ubenimex induced nuclear condensation and apoptic body in the cancer cell lines. Immunohistochemical study showed ubenimex-treated cells expressed LeY antigen which is a useful phenotypic marker predictive of apoptosis. The induction of DNA fragmentation was also observed in the ubenimex treated cancer cell lines by ELISA. We conclude that ubenimex exhibits its direct anti-tumor effect against non-small-cell lung cancer cell lines, more effectively against squamous carcinoma cell lines, through the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8952869     DOI: 10.1016/0753-3322(96)84827-x

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.

Authors:  Timothy E Andrews; Dan Wang; Daniel A Harki
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

2.  Bestatin inhibits cell growth, cell division, and spore cell differentiation in Dictyostelium discoideum.

Authors:  Yekaterina Poloz; Andrew Catalano; Danton H O'Day
Journal:  Eukaryot Cell       Date:  2012-02-17

3.  Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer.

Authors:  Shinya Ito; Ryo Miyahara; Rei Takahashi; Shinjiro Nagai; Kazumasa Takenaka; Hiromi Wada; Fumihiro Tanaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-11-12

4.  Development of bestatin-based activity-based probes for metallo-aminopeptidases.

Authors:  Michael B Harbut; Geetha Velmourougane; Gilana Reiss; Rajesh Chandramohanadas; Doron C Greenbaum
Journal:  Bioorg Med Chem Lett       Date:  2008-09-10       Impact factor: 2.823

5.  Inhibition of LTA4H by bestatin in human and mouse colorectal cancer.

Authors:  Simin Zhao; Ke Yao; Dan Li; Kangdong Liu; Guoguo Jin; Mingyang Yan; Qiong Wu; Hanyong Chen; Seung Ho Shin; Ruihua Bai; Gangcheng Wang; Ann M Bode; Ziming Dong; Zhiping Guo; Zigang Dong
Journal:  EBioMedicine       Date:  2019-05-10       Impact factor: 8.143

6.  Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions.

Authors:  Mirjana Grujić; Metka Renko
Journal:  Cancer Lett       Date:  2002-08-28       Impact factor: 8.679

Review 7.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

8.  Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer.

Authors:  Hirohisa Tsukamoto; Kiyosumi Shibata; Hiroaki Kajiyama; Mikio Terauchi; Akihiro Nawa; Fumitaka Kikkawa
Journal:  BMC Cancer       Date:  2008-03-19       Impact factor: 4.430

9.  A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.

Authors:  Masafumi Yamashita; Hiroshi Wada; Hidetoshi Eguchi; Hisataka Ogawa; Daisaku Yamada; Takehiro Noda; Tadafumi Asaoka; Koichi Kawamoto; Kunihito Gotoh; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Int J Oncol       Date:  2016-04-25       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.